297 related articles for article (PubMed ID: 5435290)
1. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
[No Abstract] [Full Text] [Related]
2. Correlation between thyroid stimulators and 3,5,3'-triiodothyronine suppressibility in patients during treatment for hyperthyroidism with thionamide drugs: comparison of assays by thyroid-stimulating and thyrotropin-displacing activities.
Kuzuya N; Chiu SC; Ikeda H; Uchimura H; Ito K; Nagataki S
J Clin Endocrinol Metab; 1979 Apr; 48(4):706-11. PubMed ID: 581876
[No Abstract] [Full Text] [Related]
3. Pituitary-thyroid function in thyrotoxic patients in relation to long-acting thyroid stimulator (LATS) levels.
Fukuchi M; Matsuoka T; Inoue T; Miyai K; Kumahara Y
Acta Endocrinol (Copenh); 1970 Dec; 65(4):577-82. PubMed ID: 5536685
[No Abstract] [Full Text] [Related]
4. Thyroid gland in Graves' disease: victim or culprit?
Chopra IJ; Solomon DH; Johnson DE; Chopra U
Metabolism; 1970 Oct; 19(10):760-72. PubMed ID: 5535910
[No Abstract] [Full Text] [Related]
5. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
[TBL] [Abstract][Full Text] [Related]
6. Thyroid suppressibility and long-acting thyroid stimulator in thyrotoxicosis.
Silverstein GE; Burke G
Arch Intern Med; 1970 Oct; 126(4):615-20. PubMed ID: 4097002
[No Abstract] [Full Text] [Related]
7. Hyperthyroidism and excessive thyrotropin secretion.
Emerson CH; Utiger RD
N Engl J Med; 1972 Aug; 287(7):328-33. PubMed ID: 4114408
[No Abstract] [Full Text] [Related]
8. [Frequency of recurrence following treatment of hyperthyroidism with methimazole and suppressibility of the thyroid gland (author's transl)].
Hackenberg K; Reinwein D; Schemmel K
Munch Med Wochenschr; 1973 Dec; 115(49):2216-8. PubMed ID: 4205415
[No Abstract] [Full Text] [Related]
9. Hyperthyroidism in Tasmania following iodide supplementation: measurements of thyroid-stimulating autoantibodies and thyrotropin.
Adams DD; Kennedy TH; Stewart JC; Utiger RD; Vidor GI
J Clin Endocrinol Metab; 1975 Aug; 41(2):221-8. PubMed ID: 51028
[TBL] [Abstract][Full Text] [Related]
10. Suppressibility of thyroid function despite high levels of long-acting thyroid stimulator.
Wong ET; Doe RP
Ann Intern Med; 1972 Jan; 76(1):77-84. PubMed ID: 4112158
[No Abstract] [Full Text] [Related]
11. Graves' disease with delayed hyperthyroidism. Onset after several years of euthyroid ophthalmopathy, dermopathy, and high serum LATS.
Chopra IJ; Solomon DH
Ann Intern Med; 1970 Dec; 73(6):985-90. PubMed ID: 5538174
[No Abstract] [Full Text] [Related]
12. T3 thyrotoxicosis. Thyrotoxicosis due to elevated serum triiodothyronine levels.
Sterling K; Refetoff S; Selenkow HA
JAMA; 1970 Jul; 213(4):571-5. PubMed ID: 4193903
[No Abstract] [Full Text] [Related]
13. Neonatal hypothyroidism and goiter in one infant of each of two sets of twins due to maternal therapy with antithyroid drugs.
Refetoff S; Ochi Y; Selenkow HA; Rosenfield RL
J Pediatr; 1974 Aug; 85(2):240-4. PubMed ID: 4135477
[No Abstract] [Full Text] [Related]
14. [Absent biological demonstration of "long-acting thyroid stimulator" (LATS) in endemic euthyroid iodine deficiency goiters].
Stelzer M; Mertz DP
Munch Med Wochenschr; 1969 Jun; 111(23):1306-9. PubMed ID: 5820134
[No Abstract] [Full Text] [Related]
15. Long-acting thyroid stimulator (LATS) in hyperthyroidism and exophthalmos.
Friis T
Dan Med Bull; 1969 Nov; 16(10):294-304. PubMed ID: 5392781
[No Abstract] [Full Text] [Related]
16. The pathogenesis of thyrotoxicosis the discovery of LATS.
Adams DD
N Z Med J; 1975 Jan; 81(531):15-7. PubMed ID: 1055308
[No Abstract] [Full Text] [Related]
17. Observations against a causal relationship between the long-acting thyroid stimulator and ophthalmopathy in Graves' disease.
McKenzie JM; McCullagh EP
J Clin Endocrinol Metab; 1968 Aug; 28(8):1177-82. PubMed ID: 4175472
[No Abstract] [Full Text] [Related]
18. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
[TBL] [Abstract][Full Text] [Related]
19. [Clinical studies on hyperthyroidism with special references to clinical-statistical surveys and studies on 131-I-triiodothyronine resin sponge uptake test and long-acting thyroid stimulator (LATS)].
Hayashida M
Sapporo Igaku Zasshi; 1966 Dec; 30(6):292-320. PubMed ID: 6010790
[No Abstract] [Full Text] [Related]
20. Clinical significance of LATS and TSH in the blood.
Lemarchand-Béraud T; Griessen M; Scazziga BR
Ann Clin Res; 1972 Jun; 4(3):121-37. PubMed ID: 4625026
[No Abstract] [Full Text] [Related]
[Next] [New Search]
